ITT analysis revealed a mOS of 10.8 months in the experimental group versus 9.7 months in the placebo group.28 Ongoing clinical trials are also exploring the efficacy of poly(ADP ribose) polymerase (PARP) inhibitors in IDH1/2 mutant iCAA (as IDH1 mutations render tumours sensitive to PARP inhibition) in order to assess their synthetic lethality and to target IDH1/2-related dependencies (ClinicalTrials.gov: NCT03212274 and NCT03878095). Here, IDH1 is linked to neoplasm.